- Home
- ARTW vs PHGE Comparison
ARTW vs PHGE Comparison
Compare ARTW & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTW
- PHGE
- Stock Information
- Founded
- ARTW 1956
- PHGE 2015
- Country
- ARTW United States
- PHGE Israel
- Employees
- ARTW N/A
- PHGE N/A
- Industry
- ARTW Industrial Machinery/Components
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- ARTW Industrials
- PHGE Health Care
- Exchange
- ARTW Nasdaq
- PHGE Nasdaq
- Market Cap
- ARTW 9.3M
- PHGE 11.0M
- IPO Year
- ARTW N/A
- PHGE N/A
- Fundamental
- Price
- ARTW $2.04
- PHGE $0.46
- Analyst Decision
- ARTW
- PHGE Strong Buy
- Analyst Count
- ARTW 0
- PHGE 1
- Target Price
- ARTW N/A
- PHGE $15.00
- AVG Volume (30 Days)
- ARTW 14.4K
- PHGE 271.1K
- Earning Date
- ARTW 07-07-2025
- PHGE 08-13-2025
- Dividend Yield
- ARTW N/A
- PHGE N/A
- EPS Growth
- ARTW N/A
- PHGE N/A
- EPS
- ARTW 0.14
- PHGE N/A
- Revenue
- ARTW $23,916,932.00
- PHGE N/A
- Revenue This Year
- ARTW N/A
- PHGE N/A
- Revenue Next Year
- ARTW N/A
- PHGE N/A
- P/E Ratio
- ARTW $40.12
- PHGE N/A
- Revenue Growth
- ARTW N/A
- PHGE N/A
- 52 Week Low
- ARTW $1.40
- PHGE $0.34
- 52 Week High
- ARTW $4.15
- PHGE $3.86
- Technical
- Relative Strength Index (RSI)
- ARTW 59.35
- PHGE 44.42
- Support Level
- ARTW $1.73
- PHGE $0.45
- Resistance Level
- ARTW $2.00
- PHGE $0.51
- Average True Range (ATR)
- ARTW 0.12
- PHGE 0.05
- MACD
- ARTW 0.01
- PHGE 0.01
- Stochastic Oscillator
- ARTW 94.07
- PHGE 55.56
About ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).